|
[1]
|
Hariharan, R., Odjidja, E.N., Scott, D., Shivappa, N., Hébert, J.R., Hodge, A., et al. (2022) The Dietary Inflammatory Index, Obesity, Type 2 Diabetes, and Cardiovascular Risk Factors and Diseases. Obesity Reviews, 23, e13349. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Huang, F., Wang, K. and Shen, J. (2019) Lipoprotein-Associated Phospholipase A2: The Story Continues. Medicinal Research Reviews, 40, 79-134. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Paik, J.K., Kim, M., Kim, M., Yen, Y., Ahn, H.Y., Lee, S., et al. (2015) Circulating Lp-PLA2 Activity Correlates with Oxidative Stress and Cytokines in Overweight/obese Postmenopausal Women Not Using Hormone Replacement Therapy. AGE, 37, Article No. 32. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Li, D., Qian, Y., Wan, L., Zhang, K., Song, L., Zhang, X., et al. (2026) Lipoprotein-associated Phospholipase A2 (lp-Pla2): A Key Hub Linking Lipid Metabolism and Immune Inflammation. Frontiers in Immunology, 17, Article 1705738. [Google Scholar] [CrossRef]
|
|
[5]
|
Zalewski, A., Nelson, J.J., Hegg, L. and Macphee, C. (2006) Lp-PLA2: A New Kid on the Block. Clinical Chemistry, 52, 1645-1650. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Racherla, S. and Arora, R. (2012) Utility of Lp-PLA2 in Lipid-Lowering Therapy. American Journal of Therapeutics, 19, 115-120. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Ait-Oufella, H., Mallat, Z. and Tedgui, A. (2014) Lp-PLA2 et sPLA2: Cardiovascular Biomarkers. Médecine/Sciences, 30, 526-531. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Bonnefont-Rousselot, D. (2016) Lp-PLA2, a Biomarker of Vascular Inflammation and Vulnerability of Atherosclerosis Plaques. Annales Pharmaceutiques Francaises, 74, 190-197.
|
|
[9]
|
Hotamisligil, G.S. (2006) Inflammation and Metabolic Disorders. Nature, 444, 860-867. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Karakas, M. and Koenig, W. (2010) Lp-PLA2 Inhibition—The Atherosclerosis Panacea? Pharmaceuticals, 3, 1360-1373. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Xepapadaki, E., Nikdima, I., Sagiadinou, E.C., Zvintzou, E. and Kypreos, K.E. (2021) HDL and Type 2 Diabetes: The Chicken or the Egg? Diabetologia, 64, 1917-1926. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
da Silva, J.F., Alves, J.V., Silva-Neto, J.A., Costa, R.M., Neves, K.B., Alves-Lopes, R., et al. (2021) Lysophosphatidylcholine Induces Oxidative Stress in Human Endothelial Cells via NOX5 Activation—Implications in Atherosclerosis. Clinical Science, 135, 1845-1858. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Yuan, Z., Li, H., Ruan, B.X., Huang, H., Li, Y. and Wang, J. (2026) Macrophage‐Derived Galectin‐3 Contributes to Pyroptosis, Apoptosis and Necroptosis through TLR4/MyD88/NF‐κB/NLRP3 during Atherosclerosis. Clinical and Translational Medicine, 16, e70637. [Google Scholar] [CrossRef]
|
|
[14]
|
Li, N.N., Xiang, S.Y., Huang, X.X., et al. (2021) Network Pharmacology-Based Exploration of Therapeutic Mechanism of Liu-Yu-Tang in Atypical Antipsychotic Drug-Induced Metabolic Syndrome. Computers in Biology and Medicine, 134, Article 104452. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Ramirez, A.V.G., Filho, D.R. and de Sá, L.B.P.C. (2021) Melatonin and Its Relationships with Diabetes and Obesity: A Literature Review. Current Diabetes Reviews, 17, e07262018413. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Babu, S., Dash, I., Badrachalam, R., et al. (2023) An Update on Diagnosis and Therapeutics for Type-2 Diabetes Mellitus. Bioinformation, 19, 295-298. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Lempesis, I.G. and Georgakopoulou, V.E. (2023) Physiopathological Mechanisms Related to Inflammation in Obesity and Type 2 Diabetes Mellitus. World Journal of Experimental Medicine, 13, 7-16. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
卢冬磊, 杨风英, 冯展鹏, 等. 同期训练可改善伴有超重或肥胖2型糖尿病患者的健康效应: 一项Meta分析[J/OL]. 中国全科医学, 1-13.
http://kns--cnki--net--https.cnki.qfsy.qfclo.com:7002/kcms2/article/abstract?v=yLAonKG4u-SeMgjs4aQWemJGBXfiJxBMQGkYQ8d-XP27i7vqs83q56yUPAeR82HmA3VR7az1xYqDoQ8LHmgJ9q2CS-WEHGgLUR3ZtX9JKgH2SggqIROReT8SMdqx057pCHYetd_zAOUvmNLC6rpJ4m--vibfrRTWKX045WvaAUZC0LRYRTw-hA==&uniplatform=NZKPT&language=CHS, 2024-09-10.
|
|
[19]
|
Kwaifa, I.K., Bahari, H., Yong, Y.K. and Noor, S.M. (2020) Endothelial Dysfunction in Obesity-Induced Inflammation: Molecular Mechanisms and Clinical Implications. Biomolecules, 10, Article 291. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Lp-PLA(2) Studies Collaboration, Thompson, A., Gao, P., et al. (2010) Lipoprotein-Associated Phospholipase A(2) and Risk of Coronary Disease, Stroke, and Mortality: Collaborative Analysis of 32 Prospective Studies. The Lancet, 375, 1536-1544.
|
|
[21]
|
Macphee, C., Benson, G.M., Shi, Y. and Zalewski, A. (2005) Lipoprotein-Associated Phospholipase A2: A Novel Marker of Cardiovascular Risk and Potential Therapeutic Target. Expert Opinion on Investigational Drugs, 14, 671-679. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Mohler, E.R., Ballantyne, C.M., Davidson, M.H., Hanefeld, M., Ruilope, L.M., Johnson, J.L., et al. (2008) The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients with Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Journal of the American College of Cardiology, 51, 1632-1641. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Jackisch, L., Kumsaiyai, W., Moore, J.D., Al-Daghri, N., Kyrou, I., Barber, T.M., et al. (2018) Differential Expression of Lp-PLA2 in Obesity and Type 2 Diabetes and the Influence of Lipids. Diabetologia, 61, 1155-1166. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Wang, G.H., Jin, J., Liu, Y.Q., et al. (2021) The Changes of Lp-PLA2 in Patients with Gestational Diabetes and Its Clinical Significance. Medicine, 100, e26786. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
凌静, 黄龑, 姜月, 等. 人血浆脂蛋白相关磷脂酶A2、同型半胱氨酸和血脂与不同肥胖类型的关系[J]. 浙江医学, 2022, 44(1): 72-75.
|
|
[26]
|
Clark, K., Sharp, S., Womack, C.J., Kurti, S.P. and Hargens, T.A. (2022) Increased Sedentary Time and Decreased Physical Activity Increases Lipoprotein Associated Phospholipase A2 in Obese Individuals. Nutrition, Metabolism and Cardiovascular Diseases, 32, 1703-1710. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Martin, M., Gaete, L., Tetzlaff, W., Ferraro, F., Lozano Chiappe, E., Botta, E.E., et al. (2022) Vascular Inflammation and Impaired Reverse Cholesterol Transport and Lipid Metabolism in Obese Children and Adolescents. Nutrition, Metabolism and Cardiovascular Diseases, 32, 258-268. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Wang, J., Yang, S. and Zhao, L. (2024) Association of High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 with Metabolically Unhealthy Phenotype: A Cross Sectional Study. Journal of Inflammation Research, 17, 81-90. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Detopoulou, P., Nomikos, T., Fragopoulou, E., Panagiotakos, D.B., Pitsavos, C., Stefanadis, C., et al. (2009) Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Activity, Platelet-Activating Factor Acetylhydrolase (PAF-AH) in Leukocytes and Body Composition in Healthy Adults. Lipids in Health and Disease, 8, Article No. 19. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
De Stefano, A., Mannucci, L., Tamburi, F., Cardillo, C., Schinzari, F., Rovella, V., et al. (2019) Lp-PLA2, a New Biomarker of Vascular Disorders in Metabolic Diseases. International Journal of Immunopathology and Pharmacology, 33, Article 2058738419827154. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Wolf, D. and Ley, K. (2019) Immunity and Inflammation in Atherosclerosis. Circulation Research, 124, 315-327. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Zhang, S.Y., Dong, Y.Q., Wang, P., et al. (2018) Adipocyte-Derived Lysophosphatidylcholine Activates Adipocyte and Adipose Tissue Macrophage Nod-Like Receptor Protein 3 Inflammasomes Mediating Homocysteine-Induced Insulin Resistance. EBioMedicine, 31, 202-216. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Pizzuto, M., Pelegrin, P. and Ruysschaert, J. (2022) Lipid-Protein Interactions Regulating the Canonical and the Non-Canonical NLRP3 Inflammasome. Progress in Lipid Research, 87, Article 101182. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Chen, Y., Li, J., Shi, J., Ning, D., Feng, J., Lin, W., et al. (2022) Ipriflavone Suppresses NLRP3 Inflammasome Activation in Host Response to Biomaterials and Promotes Early Bone Healing. Journal of Clinical Periodontology, 49, 814-827. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Motykova, E., Zlatohlavek, L., Prusikova, M., et al. (2011) Lifestyle Modification Induced Weight Loss and Changes of Cardiometabolic Risk Factors Including Lowering of Inflammatory Response in Obese Children. Neuro Endocrinology Letters, 32, 55-59.
|
|
[36]
|
吴敏, 颜申姬, 杨联君, 等. 妊娠期糖尿病患者血清Lp-PLA2、P-LAP水平与糖脂代谢指标的相关性分析[J]. 中国医学创新, 2022, 19(11): 10-13.
|
|
[37]
|
何廉旗, 周进, 于欣, 等. 血清Lp-PLA2、sST2和NT-proBNP对ACS合并糖尿病患者短期预后的临床预测价值[J]. 重庆医学, 2022, 51(15): 2561-2565.
|
|
[38]
|
Garg, S., Madhu, S. and Suneja, S. (2015) Lipoprotein Associated Phospholipase A2 Activity & Its Correlation with Oxidized LDL & Glycaemic Status in Early Stages of Type-2 Diabetes Mellitus. Indian Journal of Medical Research, 141, 107-114. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Chen, Y., Wang, S., Li, J., Fu, Y., Chen, P., Liu, X., et al. (2024) The Relationships between Biological Novel Biomarkers Lp-PLA2 and CTRP-3 and CVD in Patients with Type 2 Diabetes Mellitus. Journal of Diabetes, 16, e13574. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Feng, F., Chen, Y., Wang, G., Huang, P., Zhu, Q. and Zhou, B. (2022) Correlation of Serum CysC, IMA, and LP-PLA2 Levels with Type 2 Diabetes Mellitus Patients with Lower Extremity Atherosclerotic Occlusive Disease. Frontiers in Surgery, 9, Article 846470. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Ren, J., Chang, M., Song, S., Zhao, R., Xing, X. and Chang, X. (2022) Predictive Value of Serum Lipoprotein-Associated Phospholipase A2 for Type 2 Diabetes Mellitus Complicated with Metabolic Syndrome in Elderly Patients. Clinical Laboratory, 68. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Zhang, Z., Qian, X., Sun, Z., Cheng, C. and Gu, M. (2024) Association between Lipoprotein-Associated Phospholipase A2 and 25-Hydroxy-Vitamin D on Early Stage Diabetic Kidney Disease in Patients with Type-2 Diabetes Mellitus. Heliyon, 10, e35635. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Castagneto Gissey, L., Casella Mariolo, J.R. and Mingrone, G. (2016) How to Choose the Best Metabolic Procedure? Current Atherosclerosis Reports, 18, Article No. 43. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Chiappe, E.L., Martin, M., Iglesias Molli, A., Millan, A., Tetzlaff, W., Botta, E., et al. (2021) Effect of Roux-En-Y Gastric Bypass on Lipoprotein Metabolism and Markers of HDL Functionality in Morbid Obese Patients. Obesity Surgery, 31, 1092-1098. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Julve, J., Pardina, E., Pérez-Cuéllar, M., Ferrer, R., Rossell, J., Baena-Fustegueras, J.A., et al. (2014) Bariatric Surgery in Morbidly Obese Patients Improves the Atherogenic Qualitative Properties of the Plasma Lipoproteins. Atherosclerosis, 234, 200-205. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Ference, B.A., Robinson, J.G., Brook, R.D., Catapano, A.L., Chapman, M.J., Neff, D.R., et al. (2016) Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. New England Journal of Medicine, 375, 2144-2153. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Grundy, S.M., Stone, N.J., Bailey, A.L., et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC /ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1046-e1081.
|